Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Trine Alma Knudsen; Dennis Lund Hansen; Lukas Frans Ocias; Ole Weis Bjerrum; Mette Brabrand; Daniel El Fassi; Mikael Frederiksen; Lasse Kjaer; Thomas Kielsgaard Kristensen; Torben A. Kruse; Torben Mourits-Andersen; Peter Moller; Ulrik Malthe Overgaard; Marianne Tang Severinsen; Vibe Skov; Jesper Stentoft; Jorn Starklint; Karin de Stricker; Mads Thomassen; Thomas Stauffer Larsen; Hans Carl Hasselbalch

doi:10.1182/blood-2018-99-111255

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weis Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjaer, Thomas Kielsgaard Kristensen, Torben A. Kruse, Torben Mourits-Andersen, Peter Moller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Jesper Stentoft, Jorn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer LarsenHans Carl Hasselbalch

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Blood
Volume	132
Issue number	1
ISSN	0006-4971
DOIs	https://doi.org/10.1182/blood-2018-99-111255
Publication status	Published - 29. Nov 2018
Event	60th ASH Annual Meeting - San Diego, United States Duration: 1. Dec 2018 → 4. Dec 2018

Conference

Conference	60th ASH Annual Meeting
Country/Territory	United States
City	San Diego
Period	01/12/2018 → 04/12/2018

Documents & Links

10.1182/blood-2018-99-111255

http://www.bloodjournal.org/content/132/Suppl_1/580Licence: Unspecified

Cite this

Knudsen, T. A., Hansen, D. L., Ocias, L. F., Bjerrum, O. W., Brabrand, M., El Fassi, D., Frederiksen, M., Kjaer, L., Kristensen, T. K., Kruse, T. A., Mourits-Andersen, T., Moller, P., Overgaard, U. M., Severinsen, M. T., Skov, V., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., ... Hasselbalch, H. C. (2018). Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. Blood, 132(1). https://doi.org/10.1182/blood-2018-99-111255

@article{e3179d20b94b4c839ed231301298e4e6,

title = "Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial",

author = "Knudsen, {Trine Alma} and Hansen, {Dennis Lund} and Ocias, {Lukas Frans} and Bjerrum, {Ole Weis} and Mette Brabrand and {El Fassi}, Daniel and Mikael Frederiksen and Lasse Kjaer and Kristensen, {Thomas Kielsgaard} and Kruse, {Torben A.} and Torben Mourits-Andersen and Peter Moller and Overgaard, {Ulrik Malthe} and Severinsen, {Marianne Tang} and Vibe Skov and Jesper Stentoft and Jorn Starklint and {de Stricker}, Karin and Mads Thomassen and Larsen, {Thomas Stauffer} and Hasselbalch, {Hans Carl}",

year = "2018",

month = nov,

day = "29",

doi = "10.1182/blood-2018-99-111255",

language = "English",

volume = "132",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "1",

note = "60th ASH Annual Meeting ; Conference date: 01-12-2018 Through 04-12-2018",

}

Knudsen, TA, Hansen, DL, Ocias, LF, Bjerrum, OW, Brabrand, M, El Fassi, D, Frederiksen, M, Kjaer, L, Kristensen, TK, Kruse, TA, Mourits-Andersen, T, Moller, P, Overgaard, UM, Severinsen, MT, Skov, V, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M, Larsen, TS & Hasselbalch, HC 2018, 'Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial', Blood, vol. 132, no. 1. https://doi.org/10.1182/blood-2018-99-111255

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. / Knudsen, Trine Alma; Hansen, Dennis Lund; Ocias, Lukas Frans et al.
In: Blood, Vol. 132, No. 1, 29.11.2018.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

AU - Knudsen, Trine Alma

AU - Hansen, Dennis Lund

AU - Ocias, Lukas Frans

AU - Bjerrum, Ole Weis

AU - Brabrand, Mette

AU - El Fassi, Daniel

AU - Frederiksen, Mikael

AU - Kjaer, Lasse

AU - Kristensen, Thomas Kielsgaard

AU - Kruse, Torben A.

AU - Mourits-Andersen, Torben

AU - Moller, Peter

AU - Overgaard, Ulrik Malthe

AU - Severinsen, Marianne Tang

AU - Skov, Vibe

AU - Stentoft, Jesper

AU - Starklint, Jorn

AU - de Stricker, Karin

AU - Thomassen, Mads

AU - Larsen, Thomas Stauffer

AU - Hasselbalch, Hans Carl

PY - 2018/11/29

Y1 - 2018/11/29

U2 - 10.1182/blood-2018-99-111255

DO - 10.1182/blood-2018-99-111255

M3 - Conference abstract in journal

SN - 0006-4971

VL - 132

JO - Blood

JF - Blood

IS - 1

T2 - 60th ASH Annual Meeting

Y2 - 1 December 2018 through 4 December 2018

ER -